关键词：胰腺癌；腺体器官；外分泌腺；内分泌腺
摘 要：Pancreatic cancer is a cancer which starts from the cells of the pancreas, a glandular organ. The pancreas functions as both an exocrine and an endocrine gland. Cells in the exocrine pancreas secrete digestive enzymes into the small intestine. The endocrine pancreas produces hormones, such as glucagon and insulin, which influence glucose metabolism. Based on the site of initiation, pancreatic cancer is classified into exocrine and endocrine pancreatic cancer. When pancreatic cancer cells spread to other parts of the body, it is known as metastatic pancreatic order. The incidence and mortality rate of pancreatic cancer is higher in men than in women. SEER projected the number of new cases for pancreatic cancer in the US, in 2014, to be 46,420, accounting for 2.8 percent of new cancer cases. It also estimates that in 2014, 39,590 deaths, accounting for 6.8 percent of the total cancer deaths in the US, would be due to pancreatic cancer.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Market Segmentation by Type of Therapy

07.1.1 Chemotherapy

07.1.2 Targeted Therapy

08. Geographical Segmentation

08.1 Pancreatic Cancer Market in US

08.2 Pancreatic Cancer market in 5 EU

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape

16.1 Competitive Scenario

16.1.1 Key News

16.2 Market Share Analysis 2013

16.2.1 F. Hoffmann-La Roche

16.2.2 Pfizer

16.2.3 Novartis

16.2.4 Eli Lilly

16.2.5 Celgene

16.3 Other Prominent Vendors and Future Vendors

17. Key Vendor Analysis

17.1 Celgene

17.1.1 Key Facts

17.1.2 Business Description

17.1.3 Business Strategy

17.1.4 Business Segmentation by Revenue 2011-2013

17.1.5 Sales by Geography

17.1.6 Key Developments

17.1.7 SWOT Analysis

17.2 Eli Lilly

17.2.1 Key Facts

17.2.2 Business Overview

17.2.3 Business Segmentation by Revenue 2013

17.2.4 Business Segmentation by Revenue 2012 and 2013

17.2.5 Sales by Geography

17.2.6 Business Strategy

17.2.7 Key Developments

17.2.8 SWOT Analysis

17.3 F. Hoffmann-La Roche

17.3.1 Key Facts

17.3.2 Business Overview

17.3.3 Business Segmentation

17.3.4 Business Segmentation by Revenue 2012 and 2013

17.3.5 Geographical Segmentation by Revenue

17.3.6 Business Strategy

17.3.7 Key Information

17.3.8 SWOT Analysis

17.4 Novartis

17.4.1 Key Facts

17.4.2 Business Overview

17.4.3 Business Segmentation by Revenue 2013

17.4.4 Business Segmentation by Revenue 2012 and 2013

17.4.5 Sales by Geography

17.4.6 Business Strategy

17.4.7 Key Developments

17.4.8 SWOT Analysis

17.5 Pfizer

17.5.1 Key Facts

17.5.2 Business Description

17.5.3 Business Segmentation

17.5.4 Revenue by Business Segmentation

17.5.5 Revenue Comparison 2012 and 2013

17.5.6 Sales by Geography

17.5.7 Business Strategy

17.5.8 Key Developments

17.5.9 SWOT Analysis

18. Other Reports in this Series